Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant

Aaron N. Pham, Joseph S. Bubalo, James S. Lewis

    Research output: Contribution to journalArticle

    5 Scopus citations

    Abstract

    We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

    Original languageEnglish (US)
    Pages (from-to)6945-6947
    Number of pages3
    JournalAntimicrobial agents and chemotherapy
    Volume60
    Issue number11
    DOIs
    StatePublished - Nov 1 2016

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)
    • Infectious Diseases

    Fingerprint Dive into the research topics of 'Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant'. Together they form a unique fingerprint.

  • Cite this